TP53 and neoplasm: By integrated analysis of gene expression and genomic alteration profiles of TCGA ADC samples, we discovered that ONECUT2 overexpression was significantly associated with shorter overall survival in RAS-driven ADC patients (Fig. 1H) or patients with oncogenic alterations in the RAS signaling pathway (RAS activated) (Fig. 1I) in the presence of TP53 loss of function alterations (See the definition of RAS-driven and RAS-activated tumor in the Methods section).